Blueprint Medicines Corporation
BPMC
Κατάταξη σε μετοχές
#2355
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Τιμή μετοχής
$129.46
Τελευταίος συγχρονισμός: 2025-07-18
Κεφαλαιοποίηση
$8.36B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
0.00%
Χώρα
US
Εμπόριο Blueprint Medicines Corporation (BPMC)
Κατηγορία
Healthcare
EPS για Blueprint Medicines Corporation (BPMC)
EPS στις March 2025 TTM: $-2.47
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Blueprint Medicines Corporation, το τρέχον EPS της εταιρείας (TTM) είναι $-2.47. Στο τέλος του 2023, η εταιρεία είχε EPS $-8.37, μείωση σε σύγκριση με το EPS του 2022 που ήταν $-9.35.
Ιστορικό EPS της Blueprint Medicines Corporation από 2013 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-2.47 | 130.84% |
| 2024 | $-1.07 | -87.22% |
| 2023 | $-8.37 | -10.48% |
| 2022 | $-9.35 | -15.08% |
| 2021 | $-11.01 | -291.15% |
| 2020 | $5.76 | -183.84% |
| 2019 | $-6.87 | 27.46% |
| 2018 | $-5.39 | 37.50% |
| 2017 | $-3.92 | 48.48% |
| 2016 | $-2.64 | -8.65% |
| 2015 | $-2.89 | -6.17% |
| 2014 | $-3.08 | 92.50% |
| 2013 | $-1.60 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | -801.21% |
US
|
|
| $-7.98 | 223.08% |
US
|
|
| $-5.29 | 114.17% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,223.08% |
NL
|
